SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,057+1.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Moonray6/18/2020 10:51:48 AM
   of 642
 
Lilly commences Phase III trial of baricitinib to treat Covid-19

Eli Lilly has started patient enrolment for a Phase III clinical trial
of baricitinib to treat adults hospitalised due to Covid-19 infection.

The Phase III trial will enrol approximately 400 patients across
the US, Europe and Latin America. It will recruit patients who
do not require invasive mechanical ventilation at the time of
entering the study.

Trial participants will be given 4mg baricitinib daily or placebo
for up to 14 days or until discharge from the hospital.

The primary endpoint of the trial is the proportion of patients who
die or need non-invasive ventilation/high-flow oxygen or invasive
mechanical ventilation by day 28.

Key secondary outcomes include clinical improvement at different
time points, time to recovery, duration of hospitalisation, ventilator-
free days, and mortality over a 28-day period.

More at: Lilly commences Phase III trial of baricitinib to treat Covid-19

o~~~ O
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News